13F Holdings
中文EN

ZYBT Zhengye Biotechnology Holding Ltd Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1975641

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-12.0%
TTM net income YoY-64.0%
TTM EPS YoY-63.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin49.0%
Operating margin8.8%
Net margin6.1%
FCF margin14.7%
EBITDA margin21.8%

Returns

ROE4.1%
ROA2.3%
ROIC (approx.)5.0%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets28.5%
Debt / equity0.04x
Current ratio1.31x
Interest coverage4.07x

Cash quality & payout

Operating cash flow / net income3.63x
Accruals ratio-6.0%
Payout ratio141.7%
Capex / revenue7.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31 · USDFY20242024-12-31 · CNYFY20232023-12-31 · CNYFY20222022-12-31 · CNY
Income statement
Revenue$16.64M186.36M211.65M260.27M
Cost of revenue$13.23M95.06M94.14M112.39M
Gross profit$3.41M91.30M117.51M147.88M
R&D expense$2.58M12.79M11.90M13.42M
SG&A expense$4.43M22.57M23.59M24.32M
Operating income-$10.08M16.44M44.99M65.83M
Interest expense$486,0004.04M4.42M2.84M
Pretax income-$10.28M14.39M43.76M63.91M
Income tax$1.59M924,0006.25M8.17M
Net income-$9.98M11.31M31.46M46.73M
EBITDA-$6.38M40.60M68.90M84.63M
EPS (basic)—0.250.691.02
EPS (diluted)—0.250.691.02
Weighted avg. shares (diluted)47.35M45.67M45.67M45.67M
Balance sheet
Cash & equivalents$7.20M18.61M27.19M9.75M
Short-term investments$223,0001.43M1.22M—
Receivables$2.64M59.56M74.17M—
Inventory$5.60M58.22M58.30M—
Current assets$19.65M177.57M189.24M—
PP&E, net$33.86M255.16M263.25M—
Intangibles$6.73M14.85M16.30M—
Total assets$62.41M493.25M499.89M—
Current liabilities$17.23M135.91M150.23M—
Short-term debt$100,0007.19M79.86M—
Long-term debt$1.37M4.80M9.99M—
Total debt$1.47M11.99M89.85M—
Total liabilities$18.56M140.71M160.62M—
Shareholders' equity$35.72M283.96M272.85M356.87M
Net debt-$5.73M-6.62M62.66M—
Shares outstanding—45.67M45.67M—
Cash flow statement
Operating cash flow$1.91M41.05M48.18M17.34M
Capital expenditure$144,00013.59M7.40M27.33M
Free cash flow$1.77M27.46M40.79M-9.99M
Investing cash flow-$1.81M-27.66M-11.77M-27.33M
Financing cash flow$4.62M-22.13M-18.98M13.46M
Depreciation & amortization$3.70M24.16M23.91M18.80M
Dividends paid—16.02M39.45M21.43M

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.